ABS is developing a number of promising neurological compounds for the treatment of epilepsy, migraine, mania and neurodegenerative disorders such as Alzheimer's disease, neuropathy and stroke. These compounds are designed to meet significant unmet clinical needs in treatments for these disorders.

ABS' lead compound, ABS-103R is designed to be a next generation replacement for the widely used drug valroate. Valproate is used to treat epilepsy, migraine and mania but is associated with significant toxicity. ABS-103R is a potent single isomer analogue of a valproate specifically engineered to have the same efficacy yet without the dangerous side effects.

ABS-205 is an orally active small molecule drug that crosses the blood brain barrier and promotes nerve cell growth. The neurothrophic activity and memory enhancing effects of ABS-205 suggest that this compound is useful as a treatment for memory loss and neurodegeneration associated with aging, stroke, trauma, Alzheimer's disease and Parkinson's disease and also reduces cell division.